Tuesday, 12 April 2016 10:31

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

Written by 
Rate this item
(1 Vote)

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

A potential cure for children born with a form of an extremely rare immune-system condition often referred to as “bubble-boy disease” has moved a step closer to approval after receiving the support of a European Union regulatory panel.


The treatment, which involves inserting a new gene into the patient’s stem cells, received a positive opinion from the European Medicines Agency’s advisory committee on Friday, paving the way for final approval in coming months.

It is aimed at children with a disease known as ADA-SCID, a rare condition in which a single genetic defect prevents sufferers from developing a robust immune system, leaving them very susceptible to infections. Without treatment, they rarely live for more than two years.

Currently, the best available option is a bone-marrow transplant, but success heavily depends on how well matched the donor is. For the one in four babies who have a well matched family member, a transplant can be an effective cure. But for the rest, success rates can be as low as 50%, according to Bobby Gaspar,professor of pediatrics and immunology at London’s Great Ormond Street Hospital.

The new therapy, called Strimvelis, was developed by a group of scientists and doctors based in Milan who have used it to treat 22 children over the past 14 years. All are still alive, most without needing any further treatment. In 2010, GlaxoSmithKline PLC struck a licensing deal for the rights to market the therapy.

If approved, it would be only the second gene therapy to be sold in Europe, after UniQure NV’s Glybera for a rare genetic condition in which the body can’t break down fat molecules. No gene therapies are approved for sale in the U.S.

The ADA-SCID gene therapy has moved at a cautious pace. Scientists tested an older form of gene therapy in children with the disease as early as 1990, but suffered a setback when, around 10 years later, several of those patients developed a leukemia-like condition.

“To be recognized as a licensed medicine shows gene therapy has come a long way forward,” Dr. Gaspar said.

One complication of administering Strimvelis: For now, it can be performed only in the Milan hospital where it was developed. The procedure involves removing some stem cells from the patient, applying the gene therapy outside the body and then reinjecting them, all of which must be done in quick succession to keep within the short “shelf life” of stem cells.

Parents will probably be willing to take their babies to Milan for treatment if it is considered the best option: Children from as far away as the U.S. and the Middle East came to Italy to take part in the clinical trial, according to Martin Andrews, head of the company’s rare-disease unit. Still, Glaxo aims to eventually make the therapy available in several “hubs,” and is working on methods to increase the shelf life of stem cells so that the procedure could be done remotely, by sending the child’s stem cells to a central facility for the gene therapy, he said. Glaxo also plans to seek approval from America’s Food and Drug Administration in 2017.

While Strimvelis is unlikely to move the needle for Glaxo in terms of revenue—around 14 babies are born with the condition every year in Europe—the company is betting that the technology can be used as the basis for several new treatments, Mr. Andrews said.

Rare diseases have drawn increasing interest from drugmakers in the past few years because the industry can command high prices for effective treatments in diseases with few other available therapies.

“If efficacy is demonstrated, payers are willing to reimburse [the companies],” said Mladen Tomich, head analyst for rare diseases at health-care consultancy Decision Resources Group. “While the price tag is high the overall expenditures are still limited due to the small patient population.”

Mr. Andrews didn’t disclose Glaxo’s pricing plans for the treatment but said it was considering flexible pricing models, including amortizing the payment over several years.



Read 430177 times Last modified on Tuesday, 12 April 2016 10:52


  • Comment Link Desiree Friday, 18 August 2017 10:36 posted by Desiree

    Hello Dear, are you actually visiting this web page regularly, if so after that you will
    absolutely take nice experience.

  • Comment Link Bettye Friday, 18 August 2017 10:02 posted by Bettye

    will be the prospects buying your story catch 22 epub
    (Bettye) you are listen for it anywhere 50 shades darker epub but they go to a travel agent getting things done epub nevertheless
    sure whether you should join it harry potter and
    the order of the phoenix epub might not work a different maze runner epub

  • Comment Link twerking Friday, 18 August 2017 10:01 posted by twerking

    The dance dates back centuries, obtaining most most likely originated someplace in West Africa.

  • Comment Link Gracie Friday, 18 August 2017 09:43 posted by Gracie

    Keeρ on writing, ɡreat job!

  • Comment Link Alfonzo Friday, 18 August 2017 08:47 posted by Alfonzo

    Hello! I just wanted to ask if you ever have any problems with hackers?
    My last blog (wordpress) was hacked and I ended up losing months of hard
    work due to no backup. Do you have any methods to prevent hackers?

  • Comment Link شركة تنظيف بالطائف Friday, 18 August 2017 08:34 posted by شركة تنظيف بالطائف

    I do not know if it's just me or if perhaps everyone else experiencing
    problems with your website. It appears like
    some of the written text within your posts are running off the screen.
    Can someone else please provide feedback and let me know if this is
    happening to them as well? This may be a issue with my web
    browser because I've had this happen before. Thank you

  • Comment Link Margarita Friday, 18 August 2017 08:34 posted by Margarita

    I have fun with, cause I discovered just what I was looking for.
    You've ended my four day lengthy hunt! God Bless you man. Have
    a great day. Bye

  • Comment Link Kay Friday, 18 August 2017 08:28 posted by Kay

    I cherished up to you will obtain performed right here. Thhe carricature is tasteful,
    your authored material stylish. however, you
    command get got aan impatience over that you would like
    be delivering the following. in poor health undoubtedly
    come more in the past once more since exactly the same just about very incessantly inside case you protect this increase.

  • Comment Link Vito Friday, 18 August 2017 08:19 posted by Vito

    Wow, amazing weblog format! How long have you been running a
    blog for? you made running a blog glance easy. The full look of your site is magnificent, as
    smartly as the content!

  • Comment Link Aubrey Parham Friday, 18 August 2017 07:49 posted by Aubrey Parham

    chiropractor bloomington il

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.